$RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. Stock $rajaf

$rajaf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024059406 Filed on July 05, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$315.5K	$882.5K	$53.30K
YoY Change	491.93%	96.65%
Cost Of Revenue	$30.84K	$116.1K	$13.75K
YoY Change	124.29%	-77.47%
Gross Profit	$284.7K	$766.4K	$39.55K
YoY Change	619.75%	-1249.49%
Gross Profit Margin	90.23%	86.84%	74.2%
Selling, General & Admin	$166.7K	$541.0K	$336.2K
YoY Change	-50.43%	-6.08%
% of Gross Profit	58.55%	70.59%	850.16%
Research & Development			$118.4K
YoY Change
% of Gross Profit			299.47%
Depreciation & Amortization	$55.72K	$56.76K	$168.9K
YoY Change	-67.01%	129.23%
% of Gross Profit	19.57%	7.41%	427.05%
Operating Expenses	$166.7K	$541.0K	$454.7K
YoY Change	-63.35%	-6.08%
Operating Profit	$118.0K	$225.4K	-$415.1K
YoY Change	-128.42%	-135.07%
Interest Expense	-$26.53K	$26.54K	$10.00
YoY Change	-265400.0%	-63.03%
% of Operating Profit	-22.48%	11.77%
Other Income/Expense, Net	$460.00	-$26.07K
YoY Change		-65.97%
Pretax Income	$91.93K	$199.3K	-$415.1K
YoY Change	-122.15%	-148.01%
Income Tax	-$42.22K	-$42.22K	$0.00
% Of Pretax Income	-45.93%	-21.18%
Net Earnings	$973.4K	$823.9K	-$720.1K
YoY Change	-235.18%	-214.41%
Net Earnings / Revenue	308.53%	93.35%	-1351.01%
Basic Earnings Per Share		$0.01
Diluted Earnings Per Share	$0.00	$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	111.1M shares	111.1M shares	111.1M shares
Diluted Shares Outstanding		111.1M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.28K	$15.28K	$6.630K
YoY Change	130.47%	130.47%
Cash & Equivalents	$15.28K	$15.28K	$16.10K
Short-Term Investments
Other Short-Term Assets	$195.4K	$195.4K	$485.4K
YoY Change	-59.75%	-59.75%
Inventory			$313.5K
Prepaid Expenses
Receivables			$149.5K
Other Receivables	$120.3K		$9.502K
Total Short-Term Assets	$331.0K	$331.0K	$501.6K
YoY Change	-34.01%	-34.01%	-55.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.815M	$3.048M	$1.425M
YoY Change	97.51%	1101.7%	-16.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$42.82K	$42.82K	$1.350M
YoY Change	-96.83%	-96.83%
Total Long-Term Assets	$3.091M	$3.091M	$1.603M
YoY Change	92.81%	92.81%	-24.81%
TOTAL ASSETS
Total Short-Term Assets	$331.0K	$331.0K	$501.6K
Total Long-Term Assets	$3.091M	$3.091M	$1.603M
Total Assets	$3.422M	$3.422M	$2.105M
YoY Change	62.59%	62.59%	-35.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.808M	$2.808M	$751.1K
YoY Change	273.89%		572.48%
Accrued Expenses	$106.3K	$106.3K	$62.75K
YoY Change	69.41%	86.15%	11.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$57.11K
YoY Change
Total Short-Term Liabilities	$2.929M	$2.929M	$2.935M
YoY Change	-0.21%	16.17%	0.47%
LONG-TERM LIABILITIES
Long-Term Debt	$431.1K	$431.1K	$414.0K
YoY Change	4.13%	4.13%
Other Long-Term Liabilities	$141.0K	$141.0K	$121.1K
YoY Change	16.46%	16.46%
Total Long-Term Liabilities	$431.1K	$572.1K	$414.0K
YoY Change	4.13%	6.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.929M	$2.929M	$2.935M
Total Long-Term Liabilities	$431.1K	$572.1K	$414.0K
Total Liabilities	$3.501M	$3.501M	$3.056M
YoY Change	14.55%	14.55%	-13.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$400.7K		-$1.225M
YoY Change	-67.28%		142.74%
Common Stock	$11.11K		$11.11K
YoY Change	0.0%		11.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$78.73K	-$78.73K	-$951.3K
YoY Change
Total Liabilities & Shareholders Equity	$3.422M	$3.422M	$2.105M
YoY Change	62.59%	62.59%	-35.49%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	$973.4K	$823.9K	-$720.1K
YoY Change	-235.18%	-214.41%
Depreciation, Depletion And Amortization	$55.72K	$56.76K	$168.9K
YoY Change	-67.01%	129.23%
Cash From Operating Activities	-$1.268M	$324.7K	-$321.4K
YoY Change	294.47%	-201.03%
INVESTING ACTIVITIES
Capital Expenditures	-$1.334M	$207.4K	$480.00
YoY Change	-278054.17%	43557.68%
Acquisitions
YoY Change
Other Investing Activities	$81.40K	$85.82K
YoY Change
Cash From Investing Activities	$1.416M	-$121.6K	-$480.00
YoY Change	-295010.42%	25491.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-179.4K	-$259.6K	245.8K
YoY Change	-172.99%	-205.63%
NET CHANGE
Cash From Operating Activities	-1.268M	$324.7K	-321.4K
Cash From Investing Activities	1.416M	-$121.6K	-480.0
Cash From Financing Activities	-179.4K	-$259.6K	245.8K
Net Change In Cash	-31.58K	-$759.00	-76.07K
YoY Change	-58.49%	-99.09%
FREE CASH FLOW
Cash From Operating Activities	-$1.268M	$324.7K	-$321.4K
Capital Expenditures	-$1.334M	$207.4K	$480.00
Free Cash Flow	$66.42K	$117.3K	-$321.9K
YoY Change	-120.64%	-136.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-269315
CY2023	dei	Entity Registrant Name EntityRegistrantName	Cordyceps Sunshine Biotech Holdings Co., Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6th Fl., No. 15, Lane 548
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ruiguang Road,
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Taipei City
CY2023	dei	Entity Address Country EntityAddressCountry	TW
CY2023	dei	Security12b Title Security12bTitle	None
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111120000	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	6706
CY2023	dei	Auditor Name AuditorName	TPS Thayer LLC
CY2023	dei	Auditor Location AuditorLocation	Sugar Land, TX
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15278	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6628	usd
CY2022Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	4101	usd
CY2023Q4	cik1885680	Consumative Biological Assets ConsumativeBiologicalAssets	195359	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120336	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9502	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	481321	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	330973	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	501552	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2814766	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75510	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	233697	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	178166	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	42818	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	1349625	usd
CY2023Q4	us-gaap	Assets Assets	3422254	usd
CY2022Q4	us-gaap	Assets Assets	2104853	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2808409	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	106309	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	57109	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1378277	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1085744	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2928920	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2521130	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	431079	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	414000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	140986	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121057	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3500985	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3056187	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111120000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111120000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111120000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111120000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	11112	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11112	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	221288	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	221288	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400715	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1224575	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	89584	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	40841	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-78731	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-951334	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3422254	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2104853	usd
CY2023	us-gaap	Revenues Revenues	882533	usd
CY2022	us-gaap	Revenues Revenues	53304	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	116146	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	13746	usd
CY2023	us-gaap	Gross Profit GrossProfit	766387	usd
CY2022	us-gaap	Gross Profit GrossProfit	39558	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118444	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25052	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	238139	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	165202	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	80558	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	109295	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	47782	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	193569	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	123251	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	13777	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	541003	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	454679	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	119387	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	225384	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-415121	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-119387	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	7	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	10	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	7	usd
CY2023	us-gaap	Interest Expense InterestExpense	26535	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	459	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26069	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	199315	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-415111	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-119380	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-42221	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	241536	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-415111	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-119380	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-282761	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-304982	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-371626	usd
CY2023	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	865085	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	582324	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-304982	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-371626	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	823860	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-720093	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-491006	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	48743	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	44572	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4395	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	872603	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-675521	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-495401	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.19
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.01
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3.72
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111120000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104417534	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-12812	usd
CY2021	cik1885680	Stock Issued During Period Value Receiptof Share Subscription Receivable StockIssuedDuringPeriodValueReceiptofShareSubscriptionReceivable	10000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	222400	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-491006	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-4395	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-275813	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-720093	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	44572	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-951334	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	823860	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	48743	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-78731	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	241536	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-415111	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-119380	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56757	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24490	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	86216	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56666	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4932	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-42221	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	192634	usd
CY2022	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	4230	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	13870	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	10452	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-72808	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-56666	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4932	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	114360	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	18804	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-10815	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	196140	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-394851	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-140647	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	128549	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	73473	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-224716	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	324689	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-321378	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-365363	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	207374	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-207374	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-100000	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	85816	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-475	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-10815	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121558	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-475	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110815	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	232400	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	14643	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	309263	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	178607	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	82749	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14643	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	309263	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	328258	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-274271	usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-63476	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	246246	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-259628	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	245787	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	574504	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55738	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7518	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1064	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-759	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-83584	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	99390	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16100	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99684	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	294	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15341	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16100	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99684	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	63	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	9472	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	197	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15278	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6628	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99487	usd
CY2023	cik1885680	Recognition Of Rou Assets And Lease Liabilities RecognitionOfROUAssetsAndLeaseLiabilities	163656	usd
CY2021	cik1885680	Recognition Of Rou Assets And Lease Liabilities RecognitionOfROUAssetsAndLeaseLiabilities	261351	usd
CY2022	cik1885680	Termination Of Rou Assets And Lease Liabilities TerminationOfROUAssetsAndLeaseLiabilities	19873	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1152328.5	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	8411156.95	cny
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	582324	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as operating environment changes. Significant estimates and assumptions by management include, among others, estimated life and impairment of long-lived assets, , contingencies, valuation of inventories and income taxes including the valuation allowance for deferred tax assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0">While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.</p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0"><b>Reclassification of prior year presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations and cash flows. A reclassification has been made to the Consolidated Balance Sheet as of December 31, 2022 to reclassify short term loan of $414,000 to long term loan payable due to amendments of the loan agreements.</p>
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	414000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	0	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	0.05	pure
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	1177	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	118444	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	25052	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	89584	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	40841	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.20	pure
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0pt">Financial instruments the Company holds that are subject to concentrations of credit risk are cash, notes receivables and accounts receivable arising from its normal business activities. The Company places its cash and restricted cash in what it believes to be credit-worthy financial institutions. The Company routinely assesses the credit status of its customers and, based upon factors surrounding the credit risks, establishes an allowance, if required, for uncollectible accounts. The company believes its accounts receivable and others receivable credit risk exposure beyond such allowance is limited.</p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	823860	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-720093	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400715	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1152328.5	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	8411156.95	cny
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	865085	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-282761	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	14066	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	9502	usd
CY2023Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	106270	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120336	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9502	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2896469	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81703	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24490	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2814766	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75510	usd
CY2023	us-gaap	Depreciation Depreciation	56757	usd
CY2022	us-gaap	Depreciation Depreciation	24490	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2808409	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2781520	usd
CY2023	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	3076235	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1378277	usd
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0322	pure
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	86216	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	56666	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4932	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	77468	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	52507	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4452	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0322	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0322	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0322	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	106309	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	110853	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	30133	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	247295	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	431079	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	414000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	437550	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	437550	usd
CY2023	cik1885680	Net Income Before Provision For Income Taxes NetIncomeBeforeProvisionForIncomeTaxes	226444	usd
CY2022	cik1885680	Net Income Before Provision For Income Taxes NetIncomeBeforeProvisionForIncomeTaxes	-304982	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.20	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.20	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	45289	usd
CY2023	cik1885680	Tax Reconciliation Not Required TaxReconciliationNotRequired	-42221	usd
CY2023	cik1885680	Effective Tax Rates EffectiveTaxRates	-0.19	pure
CY2022	cik1885680	Effective Tax Rates EffectiveTaxRates	0	pure
CY2023	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases		usd
CY2022Q4	cik1885680	Consumative Biological Assets ConsumativeBiologicalAssets		usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Revenues Revenues		usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2021	us-gaap	Interest Expense InterestExpense		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.00
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.00
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.19
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.01
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-3.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104417534	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111120000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100000	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2021	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies		usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities		usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities		usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	cik1885680	Recognition Of Rou Assets And Lease Liabilities RecognitionOfROUAssetsAndLeaseLiabilities		usd
CY2023	cik1885680	Termination Of Rou Assets And Lease Liabilities TerminationOfROUAssetsAndLeaseLiabilities		usd
CY2021	cik1885680	Termination Of Rou Assets And Lease Liabilities TerminationOfROUAssetsAndLeaseLiabilities		usd
CY2022Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate		usd
CY2022	cik1885680	Tax Reconciliation Not Required TaxReconciliationNotRequired		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001885680

Files In Submission

Name	View Source	Status
0001213900-24-059406-index-headers.html	Edgar Link	pending
0001213900-24-059406-index.html	Edgar Link	pending
0001213900-24-059406.txt	Edgar Link	pending
0001213900-24-059406-xbrl.zip	Edgar Link	pending
cik1885680-20231231.xsd	Edgar Link	pending
ea0207880-20f_cordyceps.htm	Edgar Link	pending
ea020788001ex11-2_cordyceps.htm	Edgar Link	pending
ea020788001ex12-1_cordyceps.htm	Edgar Link	pending
ea020788001ex12-2_cordyceps.htm	Edgar Link	pending
ea020788001ex13-1_cordyceps.htm	Edgar Link	pending
ea020788001ex13-2_cordyceps.htm	Edgar Link	pending
ea020788001ex2-1_cordyceps.htm	Edgar Link	pending
ea020788001ex23-1_cordyceps.htm	Edgar Link	pending
ea020788001ex4-4_cordyceps.htm	Edgar Link	pending
ea020788001ex4-5_cordyceps.htm	Edgar Link	pending
ea020788001ex4-6_cordyceps.htm	Edgar Link	pending
ea020788001ex4-7_cordyceps.htm	Edgar Link	pending
ea020788001ex8-1_cordyceps.htm	Edgar Link	pending
ea020788001ex97-1_cordyceps.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
cik1885680-20231231_cal.xml	Edgar Link	unprocessable
cik1885680-20231231_def.xml	Edgar Link	unprocessable
cik1885680-20231231_pre.xml	Edgar Link	unprocessable
cik1885680-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0207880-20f_cordyceps_htm.xml	Edgar Link	completed
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. Stock $rajaf

2023 Q4 Form 20-F Financial Statement

#000121390024059406 Filed on July 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RAJAF Cordyceps Sunshine Biotech Holdings Co., Ltd. Stock $rajaf

2023 Q4 Form 20-F Financial Statement

#000121390024059406 Filed on July 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. Stock $rajaf